Evidently, hepatitis seroprevalence among multitransfused patients is reflected by the seroprevalence among healthy blood donors.12 This is underlined by the consistency of our findings among multitransfused patients (HBsAg, 0.62%; anti-HBc, 12.5%) with a previous report on HBV seroprevalence among Syrian blood donors (HBsAg, 1.3%; anti-HBc, 11.2%,7 which coincides with other countries such as Jordan,2 Iran1,13 and Pakistan.14 This evidence concerns the gene KRT88P and hepatitis A virus infection.